OPEN ACCESS

Saudi Journal of Medicine
Abbreviated Key Title: Saudi J Med
ISSN 2518-3389 (Print) | ISSN 2518-3397 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Review Article

Unveiling the Silent Threat: Investigating Delayed Physical Side Effects of COVID-19

Hossain MA[1], Naser AZM[2], Parves MM[3], Tanveer SKM[4], Rahman MM[5], Alam MR[6], Ahmed E[7], Akter T[8*]

[1]Md Alamgir Hossain, Department of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka, Bangladesh
Orcid: 0006-2193-2976
[2]Dr. A Z M Naser, Department of Pharmacy, Jahangirnagar University, Dhaka, Bangladesh
Orcid: 0009-0005-6630-5805
[3]Mohammad Masud Parves, Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka, Bangladesh
Orcid: 0009-0002-0473-0644
[4]Dr. Sharif Kamrul Md Tanveer, Department of Dentistry, Rajshahi Medical College Hospital, Rajshahi, Bangladesh
Orcid: 0009-0006-8834-4861
[5]Md Mominur Rahman, Senior Technical Advisor, Management Sciences for Health (MSH), Dhaka, Bangladesh
Orcid: 0009-0003-3646-5846
[6]Mohammad Rezwanur Alam, Department of Production, Orion Pharma Limited, Dhaka, Bangladesh
Orcid: 0009-0004-4373-8029
[7]Ehashan Ahmed, Department of Research and Publication, International Online Journal Hub Ltd., Dhaka, Bangladesh
Orcid: 0009-0006-2547-7456
[8]Tuhin Akter, Marketing & Business Development, International Online Journal Hub Ltd., Dhaka, Bangladesh
Orcid: 0000-0002-9942-5601

DOI: 10.36348/sjm.2024.v09i06.005 | **Received:** 02.05.2024 | **Accepted:** 09.06.2024 | **Published:** 12.06.2024

***Corresponding Author:** Tuhin Akter
Director of Marketing & Business Development, International Online Journal Hub (IOJH) Ltd, Dhaka, Bangladesh

Abstract

Background: Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is characterized by persistent symptoms that last weeks to months following the acute phase of COVID-19. This condition affects a substantial number of COVID-19 survivors, impacting multiple organ systems and significantly reducing quality of life. ***Method:*** This literature review synthesized research on the delayed and long-term physical side effects of COVID-19. A comprehensive search was conducted using Google Scholar and PubMed to identify open-access, English-language studies. Keywords included "COVID-19 side effects," "long COVID," and "post-acute sequelae of COVID-19." Relevant studies were screened and analyzed for key findings and limitations. ***Findings:*** The review identified significant long-term symptoms affecting COVID-19 survivors, including fatigue, dyspnea, chest pain, cognitive impairments, and musculoskeletal pain. These symptoms persist across diverse populations, regardless of the severity of the initial infection. Key limitations in existing studies include small sample sizes, single-center designs, and potential biases in self-reported data. ***Conclusion:*** Long COVID presents a major public health challenge, necessitating a multidisciplinary approach to manage its extensive and multifaceted impacts. Continued research, standardized diagnostic criteria, and comprehensive care models are essential to address the long-term needs of COVID-19 survivors and mitigate the broader economic and social burdens.

Keywords: Long COVID, post-acute sequelae of SARS-CoV-2 infection, persistent symptoms, COVID-19 side effects, literature review.

INTRODUCTION

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, emerged in December 2019 and rapidly evolved into a global health crisis. Originating in Wuhan, China, the virus quickly spread across continents, leading to widespread morbidity and mortality. By the end of 2020, COVID-19 had infected millions and caused significant disruptions to daily life worldwide [1]. The acute phase of the infection is characterized by a spectrum of symptoms, ranging from

mild to severe. Common symptoms include fever, cough, and shortness of breath, with many patients also reporting fatigue, muscle pain, and sore throat [2]. However, a notable percentage of cases progress to severe disease, requiring hospitalization and intensive care. Conditions such as acute respiratory distress syndrome (ARDS), multi-organ failure, and myocarditis have been frequently observed in severe cases, affecting a significant portion of hospitalized patients [3]. As the immediate impact of the pandemic began to be managed, attention turned towards the long-term effects of COVID-19. A substantial number of individuals who recovered from the acute phase reported persistent symptoms, a condition now widely recognized as "Long COVID" or post-acute sequelae of COVID-19 (PASC). This condition encompasses a range of long-term symptoms that can last for weeks or even months after the initial infection. Estimates of the prevalence of Long COVID vary, with reports indicating that between 5% to 80% of individuals experience lingering symptoms, depending on the severity of the initial infection and whether hospitalization was required [1,4]. Long COVID has been identified in both hospitalized and non-hospitalized patients, indicating that even those with mild cases can suffer from prolonged effects [5]. The diversity of symptoms associated with Long COVID is extensive, affecting multiple organ systems. Common long-term symptoms include respiratory issues such as chronic cough and dyspnea, cardiovascular problems like chest pain and palpitations, and neurological complaints such as headaches, cognitive impairment, and sleep disturbances [6,7]. Additionally, many patients report musculoskeletal pain, fatigue, and gastrointestinal issues, underscoring the multisystem nature of Long COVID [4,5]. The prevalence and severity of these symptoms can significantly impair the quality of life, highlighting the need for a comprehensive understanding of Long COVID. Understanding the long-term effects of COVID-19 is crucial for several reasons. Clinically, it is important to identify and manage these prolonged symptoms to improve patient outcomes. Persistent symptoms such as fatigue, cognitive impairment, and respiratory difficulties can hinder daily activities and reduce overall quality of life, necessitating ongoing medical support and interventions [8,9]. Moreover, recognizing the risk factors for Long COVID, such as the severity of the initial infection, preexisting conditions, and demographic factors, can help healthcare providers target high-risk groups for early intervention and monitoring [4,6]. The economic and social implications of Long COVID are equally significant. The prolonged nature of symptoms can lead to extended periods of work absenteeism, decreased productivity, and increased healthcare costs. Studies have shown that a substantial proportion of Long COVID patients seek medical attention for their symptoms, and many report that their ability to work is negatively impacted [10,11]. This underscores the importance of addressing Long COVID not only from a medical standpoint but also considering its broader societal impact. In conclusion, while the immediate effects of COVID-19 are well-documented, the long-term consequences are only beginning to be understood. Long COVID represents a significant challenge, affecting a large proportion of COVID-19 survivors with a wide range of symptoms that can persist for months. Continued research into the prevalence, diversity, and underlying mechanisms of Long COVID is essential to develop effective management strategies and mitigate its impact on individuals and society. This review aims to synthesize current research on the delayed physical side effects of COVID-19, providing a comprehensive overview of Long COVID and its implications for patient care and public health.

METHODS

The present review aims to synthesize existing research on the delayed physical side effects of COVID-19, specifically focusing on open-access, English-language publications. The scope of this review includes identifying, analyzing, and summarizing the key findings and limitations of relevant studies. The literature search was conducted using Google Scholar and PubMed databases to ensure comprehensive coverage of the available research. To identify relevant studies, we employed a set of keywords related to the topic, including "COVID-19 side effects," "long COVID," "post-acute sequelae of COVID-19," "SARS-CoV-2 long-term symptoms," "COVID-19 chronic effects," and "persistent COVID-19 symptoms." These keywords were chosen to capture a wide range of studies addressing the long-term physical impacts of COVID-19. The search was restricted to articles published in English to ensure accessibility and comprehension by the research team. Inclusion criteria for the studies were as follows: the studies had to be peer-reviewed, published in open-access journals, available in English, and focus on the physical side effects experienced by COVID-19 survivors. We excluded studies that were not peer-reviewed, not accessible through open access, or focused solely on psychological or social impacts without addressing physical symptoms. The initial search resulted in a large pool of articles, which were then screened based on their titles and abstracts to identify those that met the inclusion criteria. Full texts of the potentially relevant studies were retrieved and reviewed in detail. Each selected study was analyzed to extract key information, including the study design, sample size, population demographics, specific long-term physical symptoms observed, and any limitations noted by the authors.

LITERATURE REVIEW

Overview of Long COVID

Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), refers to a range of symptoms that persist for weeks or months following the acute phase of COVID-19. According to Sudre *et al.,* (2021), Long COVID is characterized by symptoms such as fatigue, headache, dyspnea, and

anosmia, lasting for at least 28 days, with some cases extending beyond 12 weeks. This condition can affect individuals irrespective of the severity of their initial infection, encompassing a wide demographic spectrum [12]. The prevalence of Long COVID varies significantly across different studies. For instance, Taquet *et al.,* (2021) conducted a study with 273,618 COVID-19 survivors and found that 57% had one or more symptoms of Long COVID within six months post-infection, with 36.55% experiencing these symptoms between three to six months. The study also noted significant differences in the incidence of Long COVID based on age, sex, and severity of the initial infection [13]. Another study by Seeßle *et al.,* (2022) reported that at 12 months post-infection, 77.1% of patients still experienced at least one persistent symptom, with reduced exercise capacity and fatigue being the most common [14]. The impact of Long COVID on health and daily life is profound. Many individuals report significant impairments in physical and mental health, which adversely affect their quality of life. Symptoms such as chronic fatigue, dyspnea, and cognitive dysfunction hinder daily activities and reduce the ability to work. A survey by Ziauddeen *et al.,* (2022) involving 2,550 participants with Long COVID found that 64.4% were unable to perform usual activities, and 37% reported a loss of income due to illness [15].

Respiratory System

Respiratory symptoms are among the most persistent and debilitating features of Long COVID. Common long-term respiratory symptoms include chronic cough, dyspnea, and reduced pulmonary function. Peghin *et al.,* (2021) reported that 37.5% of patients experienced dyspnea and 53.1% experienced fatigue up to six months post-infection [6]. Similarly, a study by Seeßle *et al.,* (2022) found that reduced exercise capacity and dyspnea were prevalent even at 12 months post-infection [14]. Pulmonary function tests and lung imaging studies have provided insights into the respiratory sequelae of Long COVID. Persistent abnormalities in lung function, such as decreased diffusion capacity, have been documented. Taquet *et al.,* (2021) highlighted that 18.71% of patients reported abnormal breathing within six months of COVID-19 diagnosis [13]. The mechanisms underlying long-term respiratory symptoms in Long COVID patients are not yet fully understood. It is hypothesized that persistent inflammation and immune response, as well as direct viral damage to lung tissue, play significant roles. Doykov *et al.,* (2020) observed a prolonged inflammatory response in patients up to 60 days post-infection, indicating ongoing immune system activation [16]. This sustained inflammation might contribute to the chronic respiratory symptoms seen in Long COVID. By comprehensively reviewing these aspects, the literature illustrates the significant and multifaceted impact of Long COVID on respiratory health. Understanding these long-term effects is crucial for developing targeted interventions and management strategies to improve the quality of life for affected individuals. The subsequent sections will delve into the cardiovascular, neurological, musculoskeletal, and gastrointestinal impacts of Long COVID, further elucidating the extensive scope of this condition.

Cardiovascular System

Long COVID often includes persistent cardiovascular symptoms such as chest pain, palpitations, and shortness of breath. A study by Charfeddine *et al.,* (2022) highlighted that fatigue, shortness of breath, and chest pain were the most common symptoms reported by patients with long-lasting endothelial dysfunction post-COVID-19 [17]. Another study by Murata *et al.,* (2022) reported that 9% of COVID-19 survivors suspected of having cardiovascular long COVID experienced symptoms such as chest pain, dyspnea, and palpitations [18]. Cardiac involvement, including myocarditis and arrhythmias, has been observed in patients with long COVID. A study by Qiao *et al.,* (2022) found that patients with moderate to severe COVID-19 had persistent cardiac symptoms, including decreased left ventricular ejection fraction and increased extracellular volumes, even one year after recovery [19]. Similarly, Doeblin *et al.,* (2022) reported significantly reduced microvascular perfusion in patients with persistent cardiac symptoms post-COVID-19, suggesting potential coronary microvascular disease [20]. The mechanisms underlying these persistent cardiovascular symptoms include chronic inflammation and autonomic dysfunction. Durstenfeld *et al.,* (2022) identified reduced exercise capacity and autonomic dysfunction as significant contributors to cardiopulmonary symptoms in long COVID patients [21]. Furthermore, Nguyen *et al.,* (2023) emphasized the role of long-lasting endothelial dysfunction and microcirculation impairment as primary mechanisms for the cardiovascular symptoms seen in long COVID [22].

Neurological and Cognitive Effects

Long COVID is frequently associated with various neurological symptoms such as headaches, dizziness, and neuropathy. In a study by Taribagil *et al.,* (2021), patients reported persistent headaches, dizziness, and other neurological issues long after the resolution of acute COVID-19 symptoms [23]. Another study by Dani *et al.,* (2021) suggested that these symptoms might be related to autonomic dysfunction caused by viral or immune-mediated disruptions [24]. Cognitive impairments, often referred to as "brain fog," are also prevalent among long COVID sufferers. Patients report issues with memory, concentration, and overall cognitive function. A study by Huang *et al.,* (2021) identified cognitive impairment as a common long-term symptom in COVID-19 survivors, affecting a substantial portion of patients [25]. Similarly, the study by Durstenfeld *et al.,* (2022) reported persistent cognitive issues among patients even several months post-infection [21]. Research into the neurological impacts of long COVID has highlighted various potential mechanisms. These

include direct viral invasion of the central nervous system, persistent inflammation, and immune responses that may contribute to ongoing neurological symptoms. The study by Corrado *et al.,* (2023) suggested that dysautonomia, a dysfunction of the autonomic nervous system, could underlie many of the neurological symptoms observed in long COVID patients [26]. Additionally, Sedat *et al.,* (2023) explored the long-term cognitive effects, identifying mental fatigue and decreased cognitive flexibility as significant issues for young adults recovering from COVID-19 [9]. In summary, the persistent cardiovascular and neurological symptoms associated with long COVID present significant challenges. Understanding the prevalence, underlying mechanisms, and effective management strategies for these symptoms is crucial for improving the quality of life for those affected. The next sections will delve into the musculoskeletal and gastrointestinal impacts of long COVID, further elucidating the extensive scope of this condition.

Musculoskeletal System

Long COVID frequently manifests with musculoskeletal symptoms such as muscle pain, joint pain, and chronic fatigue. A study by Tuzun *et al.,* (2020) reported that fatigue, myalgia, and arthralgia were common musculoskeletal symptoms observed in hospitalized COVID-19 patients. They found that 85.3% of patients experienced fatigue, 68.0% had myalgia, and 43.3% reported arthralgia, which were significantly prevalent among severe cases [27]. Similarly, Fernández-de-las-Peñas *et al.,* (2021) highlighted that myalgia at hospital admission was associated with persistent musculoskeletal pain as a long-term sequela [28]. The impact of these symptoms on physical function and mobility is significant. Chronic fatigue and muscle weakness can severely impair daily activities and reduce overall quality of life. A study by Gulzar *et al.,* (2022) found that 55% of patients reported fatigue and 39% reported myalgia six months post-infection, emphasizing the persistence of these symptoms and their debilitating effects [29]. The mechanisms underlying these musculoskeletal symptoms are not yet fully understood, but they are thought to involve inflammatory responses and immune system dysregulation. Studies suggest that chronic inflammation and direct viral damage to muscle tissue could be contributing factors. Wilson (2023) discussed the potential genetic predispositions influencing joint and muscle pain in long COVID, noting similarities with conditions like Ehlers-Danlos syndrome which involve connective tissue elements [30].

Gastrointestinal System

Long-term gastrointestinal symptoms are also common in patients with long COVID. Symptoms such as nausea, diarrhea, and abdominal pain have been frequently reported. Morello *et al.,* (2022) discussed chronic gastrointestinal symptoms in children with long COVID, highlighting abdominal pain, constipation, diarrhea, and nausea as prevalent issues [31]. Abalos and Zamora (2022) found that diarrhea was the most common GI symptom, present in 10.4% of their study population [32]. Studies have investigated the underlying mechanisms of these gastrointestinal symptoms. Song *et al.,* (2020) described the involvement of the gastrointestinal tract in COVID-19 through the ACE2 receptor, which facilitates viral entry into gastrointestinal epithelial cells [33]. Additionally, Ashcroft *et al.,* (2020) noted that COVID-19 could present with gastrointestinal symptoms that mimic surgical conditions, such as appendicitis, due to mesenteric inflammation or congestion [34].

Multisystem Effects

Long COVID is often characterized by its multisystem involvement. A study by Kingstone *et al.,* (2020) reported a wide range of persistent symptoms affecting multiple systems, including chest pain, shortness of breath, muscle and joint pains, headaches, cognitive impairment, and fatigue. These findings underscore the complexity and variability of long COVID symptoms [35]. The intersection of various symptoms can compound their effects, leading to significant challenges in patient management. Shivani *et al.,* (2022) emphasized that persistent symptoms like fatigue, dyspnea, and muscle pain were prevalent even one year post-infection, severely affecting daily activities and quality of life [5]. Furthermore, Chudzik *et al.,* (2022) highlighted that long COVID poses significant clinical and social challenges, with chronic fatigue, cough, and neurological symptoms being among the most common and debilitating manifestations [36].

Clinical Significance and Management

The clinical implications of long-term COVID-19 symptoms are profound and multifaceted, impacting multiple aspects of patients' lives. Long COVID can present with a variety of persistent symptoms including fatigue, dyspnea, chest pain, cognitive impairments, and musculoskeletal pain, which significantly reduce the quality of life. For instance, a study by Chopra *et al.,* (2021) found that fatigue and cough were among the most common persistent symptoms in patients with mild COVID-19, highlighting the need for ongoing monitoring and management of these symptoms [37]. Similarly, Ladds *et al.,* (2020) documented the lived experiences of long COVID patients, noting that many faced challenges in accessing healthcare and experienced a wide range of symptoms that required a multidisciplinary approach for effective management [38]. Management strategies for long COVID are evolving, with a focus on multidisciplinary rehabilitation and symptom-specific treatments. The use of traditional Chinese medicine (TCM) has shown promise in alleviating some long COVID symptoms. Sum *et al.,* (2023) conducted a randomized controlled trial evaluating the efficacy of a combination of Liujunzhi Decoction and Shashen Maidong Decoction in treating residual symptoms, finding significant improvements in fatigue and dyspnea [39]. Another innovative approach

is the use of the COVIDApp, which helps in the remote monitoring and management of patients in long-term care facilities, ensuring early identification and continuous care for those at high risk [40].

For effective management of long COVID, a patient-centered, multidisciplinary approach is recommended. This includes continuous monitoring, individualized rehabilitation programs, and psychological support to address the wide range of symptoms. Frontera *et al.,* (2022) highlighted the importance of tailored therapeutic strategies based on symptom clusters, suggesting that different phenotypes of long COVID may respond to specific interventions such as physical therapy, occupational therapy, or psychiatric treatments [41]. It is also essential to integrate patient feedback into care plans to ensure that their needs and experiences are adequately addressed, as suggested by Vanichkachorn *et al.,* (2021) who emphasized the role of multidisciplinary clinics in providing comprehensive care for post-COVID-19 syndrome patients [42].

Economic and Social Impact

Long COVID imposes a substantial economic burden on healthcare systems due to the need for prolonged treatment and rehabilitation. The persistence of symptoms requires frequent medical consultations, diagnostic tests, and long-term care, which significantly increases healthcare costs. Comelli *et al.,* (2022) found that a considerable number of patients reported ongoing health issues and hospital readmissions one year post-infection, which underscores the financial strain on healthcare resources [43]. The impact of long COVID extends beyond healthcare, significantly affecting workforce productivity and daily living. Persistent symptoms such as fatigue and cognitive impairments hinder individuals' ability to return to work and maintain normal daily activities. A study by Van Wambeke *et al.,* (2023) reported that despite rehabilitation efforts, a significant proportion of patients remained unable to return to work fully, with many continuing to experience severe fatigue and neurocognitive disorders [44]. The broader social implications of long COVID are significant, affecting not only individuals but also families and communities. The prolonged illness can lead to social isolation, psychological distress, and a decreased quality of life. This is particularly concerning for those with severe or multiple symptoms, who may require ongoing support and assistance. The study by Blomberg *et al.,* (2021) highlighted the persistent cognitive and respiratory symptoms in young adults, emphasizing the need for continued infection control measures and vaccination to prevent long-term sequelae in this demographic [45]. In summary, long COVID presents significant clinical, economic, and social challenges. Addressing these requires a comprehensive, multidisciplinary approach that includes effective management strategies, continuous monitoring, and tailored rehabilitation programs to support affected individuals and mitigate the broader impacts on society. Further research is essential to understand the long-term effects fully and develop effective interventions to improve outcomes for long COVID patients.

Gaps in Current Knowledge

Many existing studies on Long COVID face significant limitations that impact the generalizability and robustness of their findings. A common limitation is the variability in study design, including differences in sample sizes, follow-up durations, and the populations studied. For example, the study by Taquet *et al.,* (2021) highlights that reliance on electronic health records can introduce bias, as they may not capture all relevant clinical details and patient-reported symptoms [13]. Additionally, many studies do not account for the variability in viral strains and their specific impacts on long-term symptoms, as indicated by Saigal *et al.,* (2023), who noted the need for more detailed assessments of the impact of different SARS-CoV-2 variants [46]. Further research is necessary to understand the long-term effects of COVID-19 more comprehensively. Bilich *et al.,* (2021) suggest that more longitudinal studies are needed to track the persistence of symptoms and immune responses over extended periods [47]. There is also a need for more detailed studies that explore the mechanisms underlying long COVID symptoms, particularly those affecting multiple organ systems. Understanding the pathophysiological mechanisms can aid in developing targeted treatments and management strategies. Future studies should focus on large-scale, multi-center, and long-term cohort studies to enhance the understanding of long COVID. Mikuteit *et al.,* (2022) emphasize the importance of using innovative, patient-centered research platforms that can adapt to the ongoing pandemic situation [48]. Additionally, there is a need for research into the development of predictive models that can identify individuals at high risk of developing long COVID based on their clinical and demographic characteristics. Kessler *et al.,* (2023) suggest that machine learning approaches using electronic medical records could be valuable in this regard (Kessler *et al.,* 2023).

Table 1: Compilation of findings

Author	Year	Key Findings	Limitations
Sudre *et al.,*	2021	Long COVID characterized by symptoms lasting ≥28 days, including fatigue, headache, dyspnea, and anosmia.	Variability in symptom reporting; self-reported data
Taquet *et al.,*	2021	57% had one or more long-COVID symptoms within 6 months, with 36.55% experiencing these between 3-6 months.	Reliance on electronic health records; potential bias

Author	Year	Key Findings	Limitations
Seeßle *et al.*,	2021	77.1% of patients had persistent symptoms at 12 months, with reduced exercise capacity and fatigue being common.	Variability in patient demographics; single-center study
Ziauddeen *et al.*,	2022	64.4% unable to perform usual activities due to long COVID; 37% reported a loss of income due to illness.	Self-reported data; potential for reporting bias
Peghin *et al.*,	2021	37.5% experienced dyspnea and 53.1% experienced fatigue at 6 months post-infection.	Variability in follow-up duration; self-reported symptoms
Murata *et al.*,	2022	9% experienced persistent chest pain, dyspnea, and palpitations post-COVID, indicating potential cardiovascular sequelae.	Single-center study; potential for selection bias
Huang *et al.*,	2021	Cognitive impairment, often referred to as "brain fog," is common among COVID-19 survivors.	Self-reported data; potential for reporting bias
Sedat *et al.*,	2023	Mental fatigue and decreased cognitive flexibility are significant issues for young adults recovering from COVID-19.	Single-center study; limited generalizability
Tuzun *et al.*,	2020	Fatigue, myalgia, and arthralgia are common in hospitalized patients, with significant impacts on daily activities.	Single-center study; small sample size
Fernández-de-las-Peñas *et al.*,	2021	Myalgia at hospital admission is associated with persistent musculoskeletal pain in COVID-19 survivors at 1-year follow-up.	Single-center study; small sample size
Morello *et al.*,	2022	Chronic gastrointestinal symptoms in children with long COVID, including abdominal pain, constipation, and diarrhea.	Small sample size; single-center study
Kingstone *et al.*,	2020	Persistent symptoms affecting multiple systems, emphasizing the need for a multidisciplinary approach.	Self-reported data; potential for reporting bias
Shivani *et al.*,	2022	Persistent symptoms like fatigue and dyspnea severely affect daily activities even one-year post-infection.	Single-center study; small sample size
Chopra *et al.*,	2021	Fatigue and cough are common persistent symptoms in patients with mild COVID-19, necessitating ongoing monitoring.	Single-center study; small sample size
Van Wambeke *et al.*,	2023	Significant impact on workforce productivity, with many patients unable to return to work fully due to severe fatigue and neurocognitive disorders.	Single-center study; limited generalizability

DISCUSSION

The findings from this literature review highlight the extensive and multifaceted nature of long COVID, underscoring the importance of continued research and comprehensive management strategies. Long COVID, defined by persistent symptoms lasting weeks to months post-infection, affects a significant portion of COVID-19 survivors, irrespective of the initial severity of their illness [12]. The prevalence of long-term symptoms, as evidenced by various studies, ranges widely, with some reports indicating that up to 77.1% of patients experience persistent issues one year post-infection [14]. The spectrum of long COVID symptoms spans multiple organ systems, with fatigue, dyspnea, and cognitive impairments being the most commonly reported. These symptoms severely impact daily activities and quality of life [13,15]. Persistent cardiovascular issues, such as chest pain and palpitations, highlight the potential for long-term cardiac sequelae, which necessitate ongoing cardiovascular monitoring and management [18]. Similarly, neurological symptoms like headaches and cognitive deficits, often referred to as "brain fog," present significant challenges for survivors, affecting their ability to return to normal activities and work [9,25]. Musculoskeletal symptoms, including muscle pain and joint pain, are also prevalent, further compounding the physical burden on long COVID patients [27,28]. These findings suggest a need for integrated rehabilitation programs to address the diverse and persistent symptoms experienced by these patients. Gastrointestinal symptoms, although less frequently highlighted, remain an important aspect of long COVID, particularly in younger populations [31]. The economic and social implications of long COVID are profound. Reduced workforce productivity and increased healthcare utilization due to persistent symptoms place a considerable burden on healthcare systems and the economy [44]. This underscores the necessity for comprehensive healthcare strategies that not only address the immediate health impacts of COVID-19 but also the long-term sequelae. Despite the growing body of literature on long COVID, significant gaps remain. Many studies have limitations, including small sample sizes, single-center designs, and potential biases in self-reported data [12]. Future research should focus on large-scale, longitudinal studies to better understand the natural history of long COVID and identify effective

management strategies. Moreover, there is a critical need for standardized definitions and diagnostic criteria to ensure consistency across studies and improve the comparability of findings [48]. In conclusion, long COVID represents a significant public health challenge, with persistent symptoms affecting a substantial number of COVID-19 survivors. Addressing this issue requires a multidisciplinary approach, integrating clinical management, rehabilitation, and ongoing research to mitigate the long-term impacts of COVID-19 on individuals and society. Continued efforts to understand and manage long COVID will be essential to improve outcomes for those affected and to prepare for future public health crises.

Limitations of The Study

The study was conducted in a single hospital with a small sample size. So, the results may not represent the whole community.

CONCLUSION

The comprehensive review of the existing literature on long COVID underscores the significant and pervasive impact of persistent symptoms on COVID-19 survivors. The findings reveal that long COVID affects multiple organ systems, with symptoms such as fatigue, dyspnea, chest pain, cognitive impairments, and musculoskeletal pain being most prevalent. These long-term effects can severely diminish the quality of life and hinder daily activities. The variability in study designs and the need for standardized definitions and diagnostic criteria highlight the necessity for ongoing research to fully understand and effectively manage this condition. Addressing long COVID requires a multidisciplinary approach, integrating clinical care, rehabilitation, and continuous monitoring to mitigate its long-term impacts.

Funding: No funding sources

Conflict of interest: None declared

RECOMMENDATION

Based on the findings of this literature review, several recommendations can be made to improve the understanding and management of long COVID:

1. **Standardized Definitions and Diagnostic Criteria:** Develop and implement standardized definitions and diagnostic criteria for long COVID to ensure consistency and comparability across studies.
2. **Longitudinal Studies:** Conduct large-scale, long-term cohort studies to track the persistence and evolution of long COVID symptoms and identify risk factors and protective factors.
3. **Multidisciplinary Approach:** Implement multidisciplinary care models that integrate medical, psychological, and rehabilitative support to address the diverse needs of long COVID patients.
4. **Patient-Centered Research:** Utilize innovative, patient-centered research platforms to gather comprehensive data on long COVID symptoms and their impacts on quality of life.
5. **Public Health Strategies:** Develop public health strategies to raise awareness about long COVID, support affected individuals, and allocate resources for research and treatment.

REFERENCES

1. Yomogida, K. (2021). Post-acute sequelae of SARS-CoV-2 infection among adults aged≥ 18 years—Long Beach, California, April 1–December 10, 2020. *MMWR. Morbidity and mortality weekly report*, *70*.
2. Aloysius, M. M., Thatti, A., Gupta, A., Sharma, N., Bansal, P., & Goyal, H. (2020). COVID-19 presenting as acute pancreatitis. *Pancreatology*, *20*(5), 1026-1027.
3. Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., ... & Hu, B. (2020). Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA neurology*, *77*(6), 683-690.
4. Förster, C., Colombo, M. G., Wetzel, A. J., Martus, P., & Joos, S. (2022). Persisting symptoms after COVID-19: prevalence and risk factors in a population-based cohort. *Deutsches Ärzteblatt international*, *119*(10), 167.
5. Shivani, F. N. U., Kumari, N., Bai, P., Rakesh, F. N. U., Haseeb, M., Kumar, S., ... & Rizwan, A. (2022). Long-term symptoms of COVID-19: One-year follow-up study. *Cureus*, *14*(6).
6. Peghin, M., Palese, A., Venturini, M., De Martino, M., Gerussi, V., Graziano, E., ... & Tascini, C. (2021). Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. *Clinical Microbiology and Infection*, *27*(10), 1507-1513.
7. Merikanto, I., Dauvilliers, Y., Chung, F., Wing, Y. K., De Gennaro, L., Holzinger, B., ... & Partinen, M. (2023). Sleep symptoms are essential features of long-COVID–Comparing healthy controls with COVID-19 cases of different severity in the international COVID sleep study (ICOSS-II). *Journal of sleep research*, *32*(1), e13754.
8. Lamontagne, S. J., Winters, M. F., Pizzagalli, D. A., & Olmstead, M. C. (2021). Post-acute sequelae of COVID-19: Evidence of mood & cognitive impairment. *Brain, Behavior, & Immunity-Health*, *17*, 100347.
9. Yasin, S., Altunisik, E., & Firat, Y. E. (2023). Post-acute sequelae of COVID-19 in young adults: Mental fatigue and decreased cognitive flexibility. *Clinical Neuroscience/Ideggyogyaszati Szemle*, *76*.
10. Kadir, M., Ahmad, T., & Bass, J. (2023). Post-COVID Sequelae: From Lung Disease to Long Disease. *Cureus*, *15*(3).
11. Logue, J., Franko, N. M., Kemp, M. M., McCulloch, D. J., Chow, E. J., & Chu, H. Y. (2022, December).

284. Post-Acute Sequelae of COVID-19 Two Years After Acute Infection. In *Open Forum Infectious Diseases* (Vol. 9, No. Supplement_2, pp. ofac492-362). US: Oxford University Press.
12. Sudre, C. H., Murray, B., Varsavsky, T., Graham, M. S., Penfold, R. S., Bowyer, R. C., ... & Steves, C. J. (2021). Attributes and predictors of long COVID. *Nature medicine*, *27*(4), 626-631.
13. Taquet, M., Dercon, Q., Luciano, S., Geddes, J. R., Husain, M., & Harrison, P. J. (2021). Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS medicine*, *18*(9), e1003773.
14. Seeßle, J., Waterboer, T., Hippchen, T., Simon, J., Kirchner, M., Lim, A., ... & Merle, U. (2022). Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. *Clinical infectious diseases*, *74*(7), 1191-1198.
15. Ziauddeen, N., Gurdasani, D., O'Hara, M. E., Hastie, C., Roderick, P., Yao, G., & Alwan, N. A. (2022). Characteristics and impact of Long Covid: Findings from an online survey. *PloS one*, *17*(3), e0264331.
16. Doykov, I., Hällqvist, J., Gilmour, K. C., Grandjean, L., Mills, K., & Heywood, W. E. (2020). 'The long tail of Covid-19'-The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. *F1000Research*, *9*.
17. Charfeddine, S., Ibnhadjamor, H., Jdidi, J., Torjmen, S., Kraiem, S., Bahloul, A., ... & Abid, L. (2022). Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study. *Frontiers in cardiovascular medicine*, *9*, 866113.
18. Murata, N., Yamada, A., Fujito, H., Hashimoto, N., Nagao, T., Tanaka, Y., ... & Okumura, Y. (2022). Cardiovascular manifestations identified by multi-modality imaging in patients with long COVID. *Frontiers in Cardiovascular Medicine*, *9*, 968584.
19. Qiao, J., Zhao, P., Lu, J., Huang, L., Ma, X., Zhou, X., & Xia, L. (2022). Cardiac involvement in patients 1 year after recovery from moderate and severe COVID-19 infections. *Frontiers in Cardiovascular Medicine*, *9*, 1009637.
20. Doeblin, P., Steinbeis, F., Scannell, C. M., Goetze, C., Al-Tabatabaee, S., Erley, J., ... & Kelle, S. (2022). Brief research report: quantitative analysis of potential coronary microvascular disease in suspected long-COVID syndrome. *Frontiers in Cardiovascular Medicine*, *9*, 877416.
21. Durstenfeld, M. S., Peluso, M. J., Kaveti, P., Hill, C., Li, D., Sander, E., ... & Hsue, P. Y. (2022). Reduced Exercise Capacity, Chronotropic Incompetence, Inflammation and Symptoms in Post-Acute COVID-19.
22. Nguyen, N. N., Dudouet, P., Dhiver, C., & Gautret, P. (2023). Pericarditis related to post-acute COVID infection: A case report and review of the literature. *Acta Microbiologica et Immunologica Hungarica*, *70*(2), 100-110.
23. Taribagil, P., Creer, D. & Tahir, H. (2021). *'Long COVID' syndrome*. BMJ Case Reports CP [Internet]. 2021 Apr 1 [cited 2024 Jun 5];14(4):e241485. Available from: https://casereports.bmj.com/content/14/4/e241485
24. Dani, M., Dirksen, A., Taraborrelli, P., Torocastro, M., Panagopoulos, D., Sutton, R., & Lim, P. B. (2021). Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. *Clinical Medicine*, *21*(1), e63.
25. Huang, Y., Pinto, M. D., Borelli, J. L., Asgari Mehrabadi, M., Abrahim, H. L., Dutt, N., ... & Downs, C. A. (2022). COVID symptoms, symptom clusters, and predictors for becoming a long-hauler looking for clarity in the haze of the pandemic. *Clinical nursing research*, *31*(8), 1390-1398.
26. Corrado, J., Iftekhar, N., Halpin, S., Li, M., Tarrant, R., Grimaldi, J., ... & Sivan, M. (2023). HEART rate variability biofeedback breathing programme for LOng Covid dysautonomia (HEARTLOC): results of a feasibility study. *medRxiv*, 2023-09.
27. Tuzun, S., Keles, A., Yildiran, T., & Palamar, D. (2020). Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19.
28. Fernández-de-Las-Peñas, C., Rodríguez-Jiménez, J., Fuensalida-Novo, S., Palacios-Ceña, M., Gómez-Mayordomo, V., Florencio, L. L., ... & Arendt-Nielsen, L. (2021). Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study. *Pain*, *162*(12), 2832-2840.
29. Malik, A. M. (2022). Musculoskeletal symptoms in patients recovering from COVID-19. *Muscles, Ligaments and Tendons Journal*, *12*(1), 09-16.
30. Wilson, G. N. (2023). A gene network implicated in the joint-muscle pain, brain fog, chronic fatigue, and bowel irregularity of Ehlers-Danlos and "long" COVID19 syndromes. *medRxiv*, 2023-03.
31. Morello, R., De Rose, C., Cardinali, S., Valentini, P., & Buonsenso, D. (2022). Lactoferrin as possible treatment for chronic gastrointestinal symptoms in children with long COVID: case series and literature review. *Children*, *9*(10), 1446.
32. Abalos, J., & Zamora, S. (2022). IDDF2022-ABS-0153 Gastrointestinal manifestations and outcomes in hospitalized COVID-19 patients: a retrospective study. *Gut*, *71*(Suppl 2), A146-A146.
33. Song, Y., Liu, P., Shi, X. L., Chu, Y. L., Zhang, J., Xia, J., ... & Wang, M. Y. (2020). SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. *Gut*, *69*(6), 1143-1144.

34. Ashcroft, J., Hudson, V. E., & Davies, R. J. (2020). COVID-19 gastrointestinal symptoms mimicking surgical presentations. *Annals of Medicine and Surgery*, *56*, 108-109.
35. Kingstone, T., Taylor, A. K., O'Donnell, C. A., Atherton, H., Blane, D. N., & Chew-Graham, C. A. (2020). Finding the'right'GP: a qualitative study of the experiences of people with long-COVID. *BJGP open*, *4*(5).
36. Chudzik, M., Babicki, M., Kapusta, J., Kałuzińska-Kołat, Ż., Kołat, D., Jankowski, P., & Mastalerz-Migas, A. (2022). Long-COVID clinical features and risk factors: a retrospective analysis of patients from the STOP-COVID registry of the PoLoCOV study. *Viruses*, *14*(8), 1755.
37. Chopra, N., Chowdhury, M., Singh, A. K., Ma, K., Kumar, A., Ranjan, P., ... & Wig, N. (2021). Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India. *Drug discoveries & therapeutics*, *15*(3), 156-161.
38. Ladds, E., Rushforth, A., Wieringa, S., Taylor, S., Rayner, C., Husain, L., & Greenhalgh, T. (2020). Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. *BMC health services research*, *20*, 1-13.
39. Sum, C. H., Ching, J. Y. L., Song, T., Cheong, P. K., Lo, C. W., Lai, M. K., ... & Lin, Z. (2023). Chinese medicine for residual symptoms of COVID-19 recovered patients (long COVID)—A double-blind, randomized, and placebo-controlled clinical trial protocol. *Frontiers in medicine*, *9*, 990639.
40. Echeverría, P., Bergas, M. A. M., Puig, J., Isnard, M., Massot, M., Vedia, C., ... & Negredo, E. (2020). COVIDApp as an innovative strategy for the management and follow-up of COVID-19 cases in long-term care facilities in Catalonia: implementation study. *JMIR public health and surveillance*, *6*(3), e21163.
41. Frontera, J. A., Thorpe, L. E., Simon, N. M., de Havenon, A., Yaghi, S., Sabadia, S. B., ... & Galetta, S. L. (2022). Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study. *Plos one*, *17*(9), e0275274.
42. Vanichkachorn, G., Newcomb, R., Cowl, C. T., Murad, M. H., Breeher, L., Miller, S., ... & Higgins, S. (2021, July). Post–COVID-19 syndrome (long haul syndrome): description of a multidisciplinary clinic at Mayo clinic and characteristics of the initial patient cohort. In *Mayo clinic proceedings* (Vol. 96, No. 7, pp. 1782-1791). Elsevier.
43. Comelli, A., Viero, G., Bettini, G., Nobili, A., Tettamanti, M., Galbussera, A. A., ... & Bandera, A. (2022). Patient-reported symptoms and sequelae 12 months after COVID-19 in hospitalized adults: a multicenter long-term follow-up study. *Frontiers in Medicine*, *9*, 834354.
44. Van Wambeke, E., Bezler, C., Kasprowicz, A. M., Charles, A. L., Andres, E., & Geny, B. (2023). Two-years follow-up of symptoms and return to work in complex post-COVID-19 patients. *Journal of clinical medicine*, *12*(3), 741.
45. Blomberg, B., Mohn, K. G. I., Brokstad, K. A., Zhou, F., Linchausen, D. W., Hansen, B. A., ... & Langeland, N. (2021). Long COVID in a prospective cohort of home-isolated patients. *Nature medicine*, *27*(9), 1607-1613.
46. Saigal, A., Niklewicz, C. N., Naidu, S. B., Bintalib, H. M., Shah, A. J., Seligmann, G., ... & Mandal, S. (2023). Cross-sectional study evaluating the impact of SARS-CoV-2 variants on Long COVID outcomes in UK hospital survivors. *BMJ Open Respiratory Research*, *10*(1), e001667.
47. Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., ... & Walz, J. S. (2021). T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. *Science translational medicine*, *13*(590), eabf7517.
48. Mikuteit, M., Heinemann, S., Roder, S., Niewolik, J., Schröder, D., Vahldiek, K., ... & Steffens, S. (2022). Long-term consequences of COVID-19 and the pandemic: protocol for a web-based, longitudinal observational study (DEFEAT). *JMIR Research Protocols*, *11*(10), e38718.